KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients.

Jalid Sehouli, Alexander Mustea, Guelten Oskay-Özcelik, Maren Keller, Rolf Richter, Oliver Tomé, Hannah Woopen, Ann-Katrin Sommer-Joos, Jacek P Grabowski, Robert Armbrust, Pauline Wimberger

Cancers (Basel) 13(19) 4739

PMID34638225
PMCIDPMC8507543
DOI10.3390/cancers13194739
发表日期2021-10-13
摘要

摘要

In the single-arm non-interventional OTILIA study, patients with newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV ovarian cancer received bevacizumab (15 mg/kg every 3 weeks for up to 15 months) and standard carboplatin-paclitaxel. The primary aim was to assess safety and progression-free survival (PFS). Subgroup analyses according to age were prespecified. The analysis population included 824 patients (453 aged <70 years, 371 aged ≥70 years). At data cutoff, the median bevacizumab duration was 13.8 months. Grade ≥3 adverse events (AEs), serious AEs, and AEs leading to bevacizumab discontinuation were more common in older than younger patients, whereas treatment-related AEs were less common. Median PFS was 19.4 months, with no clear difference according to age (20.0 vs. 19.3 months in patients <70 vs. ≥70 years, respectively). One-year OS rates were 92% and 90%, respectively. Mean change from baseline in global health status/quality of life showed a clinically meaningful increase over time. In German routine oncology practice, PFS and safety were similar to reported randomized phase 3 bevacizumab trials in more selected populations. There was no notable reduction in effectiveness and tolerability in patients aged ≥70 years; age alone should not preclude use of bevacizumab-containing therapy. ClinicalTrials.gov: NCT01697488.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。